Atara Biotherapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Operational
Ebvallo™ EU Launch Activities Led by Pierre Fabre to Commence in Q1 2023Discussions with FDA Progressing on Potential U.S. BLA for Tab-cel®ATA188 Phase 2 EMBOLD Study Primary Data Readout On-Track for October 2023Cash Runway Extended into Q2 2024THOUSAND OAKS, Calif.--(BUSINESS WIRE)--$ATRA #CART--Atara Biotherapeut...
Source: pharmiweb.com